Since we previously demonstrated that PTEN is deleted in 36% of SS individuals but no mutation was detected within its coding region [20], we wondered if and how often additional genetic mechanisms potentially leading to PI3K/AKT/mTOR pathway dysregulation occurred in SS. This evidence concerns the gene PTEN and synovial sarcoma.